Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II dose-ranging study of PF-07275315 in adults with inadequately controlled moderate to severe asthma
CTR20252257Phase 2Active
- Sponsor
- Pfizer
- Start
- Jul 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of tilrekimig in asthma, sponsored by Pfizer. Started Jul 2025; status: active.
02
Drugs
tilrekimig
03
Conditions
asthma
Beyond the preview
Go deeper on CTR20252257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252257.